[The treatment of Paget's disease using salmon thyrocalcitonin. 8 cases (author's transl)]

An open trial of synthetic salmon thyrocalcitonin was carried out in 8 cases of progressive and multifocal Paget's disease over a period of three months and at a dose of 80 MRC.U twice daily. A clinical improvement was seen in half the cases. The action was also marked upon laboratory parameters with, in particular, an average decrease in alkaline phosphatase of 51% and in urinary hydroxyproline levels of 29.4%.